313 related articles for article (PubMed ID: 21835694)
1. Dosing of colistin-back to basic PK/PD.
Bergen PJ; Li J; Nation RL
Curr Opin Pharmacol; 2011 Oct; 11(5):464-9. PubMed ID: 21835694
[TBL] [Abstract][Full Text] [Related]
2. Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients.
Boisson M; Jacobs M; Grégoire N; Gobin P; Marchand S; Couet W; Mimoz O
Antimicrob Agents Chemother; 2014 Dec; 58(12):7331-9. PubMed ID: 25267660
[TBL] [Abstract][Full Text] [Related]
3. New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale.
Grégoire N; Mimoz O; Mégarbane B; Comets E; Chatelier D; Lasocki S; Gauzit R; Balayn D; Gobin P; Marchand S; Couet W
Antimicrob Agents Chemother; 2014 Dec; 58(12):7324-30. PubMed ID: 25267662
[TBL] [Abstract][Full Text] [Related]
4. Colistin in critically ill patients.
Boisson M; Gregoire N; Couet W; Mimoz O
Minerva Anestesiol; 2013 Feb; 79(2):200-8. PubMed ID: 23241733
[TBL] [Abstract][Full Text] [Related]
5. [Shedding light on the use of colistin: still gaps to be filled].
Luque S; Grau S; Berenguer N; Horcajada JP; Sorlí L; Montero MM; Salas E
Enferm Infecc Microbiol Clin; 2011 Apr; 29(4):287-96. PubMed ID: 21440335
[TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetics of Colistin Methanesulfonate and Colistin in Critically Ill Patients with Acute Renal Failure Requiring Intermittent Hemodialysis.
Jacobs M; Grégoire N; Mégarbane B; Gobin P; Balayn D; Marchand S; Mimoz O; Couet W
Antimicrob Agents Chemother; 2016 Jan; 60(3):1788-93. PubMed ID: 26729492
[TBL] [Abstract][Full Text] [Related]
7. Differences in pharmacokinetics and pharmacodynamics of colistimethate sodium (CMS) and colistin between three different CMS dosage regimens in a critically ill patient infected by a multidrug-resistant Acinetobacter baumannii.
Luque S; Grau S; Valle M; Sorlí L; Horcajada JP; Segura C; Alvarez-Lerma F
Int J Antimicrob Agents; 2013 Aug; 42(2):178-81. PubMed ID: 23769664
[TBL] [Abstract][Full Text] [Related]
8. Optimizing colistin dosing: Is a loading dose necessary?
Nazer LH; Anabtawi N
Am J Health Syst Pharm; 2017 Jan; 74(1):e9-e16. PubMed ID: 28007716
[TBL] [Abstract][Full Text] [Related]
9. Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients.
Karaiskos I; Friberg LE; Pontikis K; Ioannidis K; Tsagkari V; Galani L; Kostakou E; Baziaka F; Paskalis C; Koutsoukou A; Giamarellou H
Antimicrob Agents Chemother; 2015 Dec; 59(12):7240-8. PubMed ID: 26369974
[TBL] [Abstract][Full Text] [Related]
10. Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration.
Imberti R; Cusato M; Villani P; Carnevale L; Iotti GA; Langer M; Regazzi M
Chest; 2010 Dec; 138(6):1333-9. PubMed ID: 20558557
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic evaluation of colistin sodium.
Michalopoulos AS; Karatza DC; Gregorakos L
Expert Opin Drug Metab Toxicol; 2011 Feb; 7(2):245-55. PubMed ID: 21128824
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy and pharmacokinetics of colistimethate sodium and colistin in critically ill patients in an Indian hospital with high endemic rates of multidrug-resistant Gram-negative bacterial infections: A prospective observational study.
Moni M; Sudhir AS; Dipu TS; Mohamed Z; Prabhu BP; Edathadathil F; Balachandran S; Singh SK; Prasanna P; Menon VP; Patel T; Patel P; Kaye KS; Menon VP
Int J Infect Dis; 2020 Nov; 100():497-506. PubMed ID: 32781161
[TBL] [Abstract][Full Text] [Related]
13. Polymyxins for the treatment of extensively-drug-resistant Gram-negative bacteria: from pharmacokinetics to bedside.
Zavascki AP
Expert Rev Anti Infect Ther; 2014 May; 12(5):531-3. PubMed ID: 24666285
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria.
Plachouras D; Karvanen M; Friberg LE; Papadomichelakis E; Antoniadou A; Tsangaris I; Karaiskos I; Poulakou G; Kontopidou F; Armaganidis A; Cars O; Giamarellou H
Antimicrob Agents Chemother; 2009 Aug; 53(8):3430-6. PubMed ID: 19433570
[TBL] [Abstract][Full Text] [Related]
15. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing.
Lim LM; Ly N; Anderson D; Yang JC; Macander L; Jarkowski A; Forrest A; Bulitta JB; Tsuji BT
Pharmacotherapy; 2010 Dec; 30(12):1279-91. PubMed ID: 21114395
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients.
Garonzik SM; Li J; Thamlikitkul V; Paterson DL; Shoham S; Jacob J; Silveira FP; Forrest A; Nation RL
Antimicrob Agents Chemother; 2011 Jul; 55(7):3284-94. PubMed ID: 21555763
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of nebulized colistin methanesulfonate in critically ill patients.
Boisson M; Grégoire N; Cormier M; Gobin P; Marchand S; Couet W; Mimoz O
J Antimicrob Chemother; 2017 Sep; 72(9):2607-2612. PubMed ID: 28575278
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetic analysis of colistin in burn patients.
Lee J; Han S; Jeon S; Hong T; Song W; Woo H; Yim DS
Antimicrob Agents Chemother; 2013 May; 57(5):2141-6. PubMed ID: 23439640
[TBL] [Abstract][Full Text] [Related]
19. Steady-state pharmacokinetic and pharmacodynamic profiling of colistin in critically ill patients with multi-drug-resistant gram-negative bacterial infections, along with differences in clinical, microbiological and safety outcome.
Ram K; Sheikh S; Bhati RK; Tripathi CD; Suri JC; Meshram GG
Basic Clin Pharmacol Toxicol; 2021 Jan; 128(1):128-140. PubMed ID: 33245629
[TBL] [Abstract][Full Text] [Related]
20. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill.
Mohamed AF; Karaiskos I; Plachouras D; Karvanen M; Pontikis K; Jansson B; Papadomichelakis E; Antoniadou A; Giamarellou H; Armaganidis A; Cars O; Friberg LE
Antimicrob Agents Chemother; 2012 Aug; 56(8):4241-9. PubMed ID: 22615285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
